Connect with us

Biotech

Health Ministry Approves First Clinical Trial of a Spanish Covid-19 Vaccine

Before being authorized, the vaccine developed by Hipra will have to pass stage I/II, where its safety will have to be demonstrated. Phase III will then be carried out with thousands of volunteers to demonstrate efficacy. Once this point has been reached, the company will have to convince the various governments or corresponding bodies to buy its vaccine.

Published

on

The first Spanish vaccine against COVID-19 is now a little closer to become a reality. The Ministry of Health has approved the use of the vaccine of Hipra, a company based in Girona, in patient trials after leaving behind laboratory tests on animals.

The Spanish Agency for Medicines and Health Products (Aemps), which reports to the Ministry of Health, has authorized the clinical trial of the company’s PHH-1V vaccine, according to a press release from the Aemps.

In total, the administration has earmarked $22.3 million (€19 million) with the aim of collaborating with Spanish science in the creation of the new Covid-19 vaccines, according to the President of the Government, Pedro Sánchez.

Hipra plans to produce 400 million doses during 2022 and to reach 1.2 billion in 2023. The doses will be kept between two and eight degrees Celsius, a fact that could facilitate logistics and distribution.

If you want to find more details about the first coronavirus vaccine developed by Hipra and to be the first to read the most important business news of the day, download for free our companion app Born2Invest.

Before being authorized, the vaccine will have to pass stage I/II, where its safety will have to be demonstrated

The company is also carrying out another line of research in collaboration with the Hospital Clínic de Barcelona with the aim of developing a vaccine against Covid-19 based on the mRNA of the virus.

Before being authorized, the vaccine will have to pass stage I/II, where its safety will have to be demonstrated. Phase III will then be carried out with thousands of volunteers to demonstrate efficacy before the European Medicines Agency (EMA) can give its approval.

SEE ALSO  Strong yields a possible turning point for corn

Once this point has been reached, the company will have to convince the various governments or corresponding bodies to buy its vaccine. The Ministry of Health has clarified that it will be necessary to wait for the data from the different trials in order to be able to analyze all the data and draw conclusions.

Hipra was founded in 1954 and ranks sixth in the world ranking of animal health vaccines, according to data provided by the company. In the last decade, it has launched 22 veterinary vaccines. The company had a turnover of 319 million euros in 2020, which translates into an increase of 15.2% over the previous year. Hipra has two factories, one in Amer (Girona) and another in Brazil. In total, the company has 2,000 employees.

__

(Featured image by spencerbdavis1 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Michael Jermaine Cards is a business executive and a financial journalist, with a focus on IT, innovation and transportation, as well as crypto and AI. He writes about robotics, automation, deep learning, multimodal transit, among others. He updates his readers on the latest market developments, tech and CBD stocks, and even the commodities industry. He does management consulting parallel to his writing, and has been based in Singapore for the past 15 years.